A new efficacious Mcl-1 inhibitor maximizes bortezomib and venetoclax responsiveness in resistant multiple myeloma cells
O. S. F. Al Odat, K. Gowda, S. K. Srivastava, S. G. Amin, S. C. Jonnalagadda, T. Budak-Alpdogan, M. K. Pandey
This paper identifies KS18, a Mcl-1 inhibitor, as a potential treatment for multiple myeloma, showing it enhances apoptosis and overcomes resistance to bortezomib and venetoclax in resistant cells and mouse models.
bioRxiv · Dec 6, 2023 · PreprintPharmacology & Toxicology